{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:55:27Z","timestamp":1766022927926,"version":"3.48.0"},"reference-count":35,"publisher":"e-Century Publishing Corporation","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/eaaf2821","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T03:47:41Z","timestamp":1740714461000},"page":"1311-1320","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent chemoradiotherapy plus immunotherapy for locally advanced non-small-cell lung cancer: clinical efficacy and prognostic analysis"],"prefix":"10.62347","volume":"17","author":[{"given":"Xiangning","family":"Lan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y and Zhou C. Non-small cell lung cancer in China. Cancer Commun (Lond) 2022; 42: 937-970.","journal-title":"Cancer Commun (Lond)"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/bph.16257","article-title":"Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer","volume":"181","author":"Gyorffy","year":"2024","unstructured":"Gyorffy B. Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer. Br J Pharmacol 2024; 181: 362-374.","journal-title":"Br J Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.xjon.2022.03.004","article-title":"Survival after recurrence following surgical resected non-small cell lung cancer: a multicenter, prospective cohort study","volume":"10","author":"Takenaka","year":"2022","unstructured":"Takenaka T, Yano T, Yamazaki K, Okamoto T, Hamatake M, Shimokawa M and Mori M; Kyushu University Lung Surgery Study Group Japan. Survival after recurrence following surgical resected non-small cell lung cancer: a multicenter, prospective cohort study. JTCVS Open 2022; 10: 370-381.","journal-title":"JTCVS Open"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: State of the art and future directions","volume":"44","author":"Miao","year":"2024","unstructured":"Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W and Xia Y. Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond) 2024; 44: 23-46.","journal-title":"Cancer Commun (Lond)"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.ijrobp.2022.10.014","article-title":"Randomized, multicenter, phase 3 study of accelerated fraction radiation therapy with concomitant boost to the gross tumor volume compared with conventional fractionation in concurrent chemoradiation in patients with unresectable stage III non-small cell lung cancer: The Korean Radiation Oncology Group 09-03 Trial","volume":"115","author":"Kim","year":"2023","unstructured":"Kim YH, Ahn SJ, Moon SH, Kim JH, Kim YC, Oh IJ, Park CK, Jeong JU, Yoon MS, Song JY, Suh CO, Cho KH and Park SH. Randomized, multicenter, phase 3 study of accelerated fraction radiation therapy with concomitant boost to the gross tumor volume compared with conventional fractionation in concurrent chemoradiation in patients with unresectable stage III non-small cell lung cancer: The Korean Radiation Oncology Group 09-03 Trial. Int J Radiat Oncol Biol Phys 2023; 115: 873-885.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s12885-022-09717-8","article-title":"A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer","volume":"22","author":"Zheng","year":"2022","unstructured":"Zheng Q, Min S and Zhou Y. A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer. BMC Cancer 2022; 22: 674.","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pulmoe.2019.11.007","article-title":"The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer","volume":"27","author":"Sakin","year":"2021","unstructured":"Sakin A, Sahin S, Atci MM, Sakin A, Yasar N, Geredeli C, Aksaray F and Cihan S. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology 2021; 27: 26-34.","journal-title":"Pulmonology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.21873\/anticanres.16205","article-title":"Comparison of the efficacy and toxicity of concurrent chemoradiotherapy and durvalumab and concurrent chemoradiotherapy alone for locally advanced non-small cell lung cancer With N3 lymph node metastasis","volume":"43","author":"Abe","year":"2023","unstructured":"Abe T, Iino M, Saito S, Aoshika T, Ryuno Y, Ohta T, Igari M, Hirai R, Kumazaki YU, Miura YU, Kaira K, Kagamu H, Noda SE and Kato S. Comparison of the efficacy and toxicity of concurrent chemoradiotherapy and durvalumab and concurrent chemoradiotherapy alone for locally advanced non-small cell lung cancer With N3 lymph node metastasis. Anticancer Res 2023; 43: 675-682.","journal-title":"Anticancer Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/jcm11092629","article-title":"Neoadjuvant chemo-immunotherapy for locally advanced non-small-cell lung cancer: a review of the literature","volume":"11","author":"Franzi","year":"2022","unstructured":"Franzi S, Mattioni G, Rijavec E, Croci GA and Tosi D. Neoadjuvant chemo-immunotherapy for locally advanced non-small-cell lung cancer: a review of the literature. J Clin Med 2022; 11: 2629.","journal-title":"J Clin Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2318815","DOI":"10.1080\/21645515.2024.2318815","article-title":"Immune regulation and the tumor microenvironment in anti-PD-1\/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: a bibliometric analysis","volume":"20","author":"Huang","year":"2024","unstructured":"Huang Y, Chen Z, Shen G, Fang S, Zheng J, Chi Z, Zhang Y, Zou Y, Gan Q, Liao C, Yao Y, Kong J and Fan X. Immune regulation and the tumor microenvironment in anti-PD-1\/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: a bibliometric analysis. Hum Vaccin Immunother 2024; 20: 2318815.","journal-title":"Hum Vaccin Immunother"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Zhang L, Mai W, Hao B, Jiang W and Geng Q. Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: a case report. Medicine (Baltimore) 2020; 99: e19790.","DOI":"10.1097\/MD.0000000000019790"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.2217\/fon-2021-1336","article-title":"Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer","volume":"18","author":"Zhang","year":"2022","unstructured":"Zhang L, Qian Y, Li J, Cui C, Chen L, Qu S and Lu S. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Future Oncol 2022; 18: 1896-1905.","journal-title":"Future Oncol"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Alduais Y, Zhang H, Fan F, Chen J and Chen B. Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment. Medicine (Baltimore) 2023; 102: e32899.","DOI":"10.1097\/MD.0000000000032899"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/pmrj.12741","article-title":"Translation of Karnofsky Performance Status (KPS) for use in inpatient cancer rehabilitation","volume":"15","author":"McNair","year":"2023","unstructured":"McNair KM, Zeitlin D, Slivka AM, Lequerica AH and Stubblefield MD. Translation of Karnofsky Performance Status (KPS) for use in inpatient cancer rehabilitation. PM R 2023; 15: 65-68.","journal-title":"PM R"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Hu Q, Wang S, Ma L, Sun Z, Liu Z, Deng S and Zhou J. Radiological assessment of immunotherapy effects and immune checkpoint-related pneumonitis for lung cancer. J Cell Mol Med 2024; 28: e17895.","DOI":"10.1111\/jcmm.17895"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Guberti M, Schiroli D, Marraccini C, Mazza G, Iotti C, Baricchi R, Iotti B and Merolle L. Homologous platelet gel on radiation-induced dermatitis in a patient receiving head and neck radiotherapy plus cetuximab: a case report. Medicine (Baltimore) 2023; 102: e34779.","DOI":"10.1097\/MD.0000000000034779"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12967-022-03256-3","article-title":"Tumor angiogenesis at baseline identified by (18)F-Alfatide II PET\/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"20","author":"Wei","year":"2022","unstructured":"Wei Y, Qin X, Liu X, Zheng J, Luan X, Zhou Y, Yu J and Yuan S. Tumor angiogenesis at baseline identified by (18)F-Alfatide II PET\/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. J Transl Med 2022; 20: 63.","journal-title":"J Transl Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"112947","DOI":"10.1016\/j.ejca.2023.112947","article-title":"Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: analysis of a real-life intention-to-treat population","volume":"190","author":"Jongbloed","year":"2023","unstructured":"Jongbloed M, Bartolomeo V, Steens M, Dursun S, van de Lisdonk T, De Ruysscher DKM and Hendriks LEL. Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: analysis of a real-life intention-to-treat population. Eur J Cancer 2023; 190: 112947.","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00432-021-03896-w","article-title":"Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: a single-arm, phase 2 trial","volume":"149","author":"Sun","year":"2023","unstructured":"Sun C, Liu Y, Zhang P, Wang X, Xu Y, Lin X, Ma X, Guo Y, Qiu S, Shao G, Yang Z and Ma K. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. J Cancer Res Clin Oncol 2023; 149: 819-831.","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/jrr\/rrab063","article-title":"Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer","volume":"62","author":"Abe","year":"2021","unstructured":"Abe T, Iino M, Saito S, Aoshika T, Ryuno Y, Ohta T, Igari M, Hirai R, Kumazaki Y, Miura Y, Kaira K, Kagamu H, Noda SE and Kato S. Feasibility of intensity modulated radiotherapy with involved field radiotherapy for Japanese patients with locally advanced non-small cell lung cancer. J Radiat Res 2021; 62: 894-900.","journal-title":"J Radiat Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1634\/theoncologist.2016-0155","article-title":"Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung cancer compared with three-dimensional conformal radiation therapy","volume":"21","author":"Wang","year":"2016","unstructured":"Wang J, Zhou Z, Liang J, Feng Q, Xiao Z, Hui Z, Wang X, Lv J, Chen D, Zhang H, Ji Z, Cao J, Liu L, Jiang W, Men Y, Xu C, Dai J, Yin W and Wang L. Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung cancer compared with three-dimensional conformal radiation therapy. Oncologist 2016; 21: 1530-1537.","journal-title":"Oncologist"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.radonc.2021.11.033","article-title":"Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: clinical outcomes and theoretical results from an extended LQ and TCP model","volume":"167","author":"Ai","year":"2022","unstructured":"Ai X, Qiu B, Zhou Y, Li S, Li Q, Huan J, Li J, Hu N, Chen N, Liu F, Wang D, Chu C, Wang B, Chen L, Jiang H, Huang S, Huang X, Bi N and Liu H. Comparison and quantification of different concurrent chemotherapy regimens with radiotherapy in locally advanced non-small cell lung cancer: clinical outcomes and theoretical results from an extended LQ and TCP model. Radiother Oncol 2022; 167: 34-41.","journal-title":"Radiother Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1080\/13696998.2022.2071066","article-title":"Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China","volume":"25","author":"Rui","year":"2022","unstructured":"Rui M, Fei Z, Wang Y, Zhang X, Ma A, Sun H and Li H. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China. J Med Econ 2022; 25: 618-629.","journal-title":"J Med Econ"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3208780","DOI":"10.1155\/2022\/3208780","article-title":"Systematic evaluation meta-analysis of the efficacy of recombinant human endostatin combined with gemcitabine and cisplatin in non-small-cell lung cancer","volume":"2022","author":"Zhang","year":"2022","unstructured":"Zhang L, He Y, Yi C and Huang M. Systematic evaluation meta-analysis of the efficacy of recombinant human endostatin combined with gemcitabine and cisplatin in non-small-cell lung cancer. J Healthc Eng 2022; 2022: 3208780.","journal-title":"J Healthc Eng"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Naidoo J, Nishino M, Patel SP, Shankar B, Rekhtman N, Illei P and Camus P. Immune-related pneumonitis after chemoradiotherapy and subsequent immune checkpoint blockade in unresectable stage III non-small-cell lung cancer. Clin Lung Cancer 2020; 21: e435-e444.","DOI":"10.1016\/j.cllc.2020.02.025"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","article-title":"Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Zhou","year":"2022","unstructured":"Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Cui N, Wang J, Wang Q, Zhang R, Yang J and Wu YL. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2022; 23: 209-219.","journal-title":"Lancet Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/1759-7714.13333","article-title":"Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: updated follow-up results from two phase II trials","volume":"11","author":"Honglian","year":"2020","unstructured":"Honglian M, Zhouguang H, Fang P, Lujun Z, Dongming L, Yujin X, Yong B, Liming X, Yirui Z, Xiao H, Jin W, Yue K, Lvhua W and Ming C. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: updated follow-up results from two phase II trials. Thorac Cancer 2020; 11: 898-906.","journal-title":"Thorac Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"SJ","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA and Ozguroglu M; PACIFIC Investigators. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377: 1919-1929.","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"SJ","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA and Ozguroglu M; PACIFIC Investigators. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018; 379: 2342-2350.","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13014-019-1453-3","article-title":"Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy","volume":"15","author":"Gennen","year":"2020","unstructured":"Gennen K, Kasmann L, Taugner J, Eze C, Karin M, Roengvoraphoj O, Neumann J, Tufman A, Orth M, Reu S, Belka C and Manapov F. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat Oncol 2020; 15: 5.","journal-title":"Radiat Oncol"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Wang J, Xia TY, Wang YJ, Li HQ, Li P, Wang JD, Chang DS, Liu LY, Di YP, Wang X and Wu WZ. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011; 81: e59-65.","DOI":"10.1016\/j.ijrobp.2010.12.035"},{"key":"ref31","unstructured":"Chen WJ, Zhang EN, Zhong ZK, Jiang MZ, Yang XF, Zhou DM and Wang XW. MicroRNA-153 expression and prognosis in non-small cell lung cancer. Int J Clin Exp Pathol 2015; 8: 8671-8675."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Liu N, Mao J, Tao P, Chi H, Jia W and Dong C. The relationship between NLR\/PLR\/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022; 101: e28617.","DOI":"10.1097\/MD.0000000000028617"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Sert F, Cosgun G, Yalman D and Ozkok S. Can we define any marker associated with brain failure in patients with locally advanced non-small cell lung cancer? Cancer Radiother 2021; 25: 316-322.","DOI":"10.1016\/j.canrad.2020.11.002"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1007\/s00268-012-1766-y","article-title":"Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer","volume":"36","author":"Kawai","year":"2012","unstructured":"Kawai H and Ota H. Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg 2012; 36: 2853-2857.","journal-title":"World J Surg"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/2\/ajtr0162345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:34Z","timestamp":1766022634000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/2\/ajtr0162345.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/eaaf2821","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2025]]}}}